Suchergebnisse - "Nilsson, Monique B"

PubPharm (48)

21

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

enthalten in: Cancer cell | 2019

von Robichaux, J. | Elamin, Y. | Vijayan, R. | +28

ErratumIn: Cancer Cell. 2020 Mar 16;37(3):420. - PMID 32183953

22

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Le, X. | Puri, S. | Negrao, M. | +21

CommentIn: Clin Cancer Res. 2018 Dec 15;24(24):6112-6114. - PMID 30352903

23

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer

enthalten in: Nature medicine | 2018

von Robichaux, J. | Elamin, Y. | Tan, Z. | +21

CommentIn: Nat Rev Clin Oncol. 2018 Jul;15(7):404. - PMID 29743681

24

Stress hormones promote EGFR inhibitor resistance in NSCLC : Implications for combinations with β-blockers

enthalten in: Science translational medicine | 2017

von Nilsson, M. | Sun, H. | Diao, L. | +22

CommentIn: Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S117-S122. - PMID 29782563

25

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2017

von Cascone, T. | Xu, L. | Lin, H. | +22

26

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Nilsson, M. | Giri, U. | Gudikote, J. | +15

27

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

enthalten in: Clinical cancer research | 2016

von Nilsson, M. | Giri, U. | Gudikote, J. | +15

28

VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2014

von Riquelme, E. | Suraokar, M. | Behrens, C. | +11

29

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2Targeted Therapy

enthalten in: Clinical cancer research | 2014

von Riquelme, E. | Suraokar, M. | Behrens, C. | +11

30

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2013

von Byers, L. | Diao, L. | Wang, J. | +31

CommentIn: Clin Cancer Res. 2013 Jan 1;19(1):3-5. - PMID 23172883